Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Breast 1

Conditions

Breast Neoplasms 555Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Leukemia 346Multiple Myeloma 336Lymphoma, Non-Hodgkin 317Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma, Follicular 241Burkitt Lymphoma 217Myelodysplastic Syndromes 211Lymphoma, Mantle-Cell 202Hodgkin Disease 193Recurrence 155Lymphoma, B-Cell, Marginal Zone 142Melanoma 136Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 94Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Cognitive Training 2Vitamin D 1Tobacco Use Cessation Devices 1Synbiotics 1Sodium Chloride 1Saline Solution 1Prebiotics 1Palliative Care 1Neuroprotective Agents 1Mesna 1Magnetic Resonance Spectroscopy 1High-Intensity Interval Training 1Functional Status 1Electroacupuncture 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Ashwagandha 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chemotherapy-Related Cognitive Impairment × Cyclophosphamide × Clear all
NCT01205503 2016-02-24

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

University of Kentucky

Phase 2 Completed
32 enrolled 24 charts
BreastLymphoid

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡